[1] WAN JJ, DIAO Q, XU F, et al.Finerenone: a Novel Aldosterone Receptor Antagonist for the Treatment of Diabetic Nephropathy[J].Herald of Medicine(医药导报),2022, 41(10): 1486-1490. [2] Committee of Chinese Expert Consensus on the Use of Finerenone in Patients with Diabetes Mellitus and Chronic Kidney Disease. Chinese Expert Consensus on the Use of Finerenone in Patients with Diabetes Mellitus and Chronic Kidney Disease(2023 edition)[J].Chinese Journal of Diabetes Mellitus(中华糖尿病杂志),2023, 15(10): 907-916. [3] LIN Y, TANG LD.A Novel Mineralocorticoid Receptor Antagonists: Finerenone[J].Chinese Journal of New Drugs and Clinical Remedies (中国新药与临床杂志),2022, 41(12): 729-732. [4] BAKRIS GL, AGARWAL R, ANKER SD, et al.Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes[J].N Engl J Med, 2020, 383(23): 2219-2229. [5] AGARWAL R, FILIPPATOS G, PITT B, et al.Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: the FIDELITY Pooled Analysis[J].Eur Heart J, 2022, 43(6): 474-484. [6] BAKRIS GL, AGARWAL R, ANKER SD, et al.Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial[J].Am J Nephrol, 2019, 50(5): 333-344. [7] TAN YJ, REN WQ, YAO SS, et al.One Case of Hemolytic Anemia Caused by Atorvastatin Calcium Tablets[J].Central South Pharmacy, 2022, 20(7): 1710-1712. [8] HEINIG R, EISSING T.The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone[J].Clin Pharmacokinet, 2023, 62(12): 1673-1693. [9] HEINIG R, FRICKE R, WERTZ S, et al.Results from Drug-Drug Interaction Studies in vitro and in vitro Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3[J].Eur J Drug Metab Pharmacokinet, 2022, 47(6): 803-815. [10] YANG FF, ZHAO YL, XIE J, et al.Strictly Implement the Grading Management of Antibiotics to Promote Rational Drug Use in Patients with Liver Diseases[J].Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析),2017, 17(2): 156-157. [11] LENTINI S, HEINIG R, KIMMESKAMP-KIRSCHBAUM N, et al.Pharmacokinetics, Safety and Tolerability of the Novel, Selective Mineralocorticoid Receptor Antagonist Finerenone - Results from First-in-Man and Relative Bioavailability Studies[J].Fundam Clin Pharmacol, 2016, 30(2): 172-184. [12] TAN ZR, ZHOU G, ZHOU HH.Influence of Chronic Liver Disease on the Activity of CYP450s[J].Chinese Journal of New Drugs(中国新药杂志),2008(14): 1203-1205. [13] LIU Y, LIN HL.Renal Anemia and Inflammation in Patients with Chronic Kidney Disease[J].Chinese Journal of Practical Internal Medicine(中国实用内科杂志),2020, 40(11): 908-911. [14] AHN J, LEE S, WON S. Possible Link between Statin and Iron Deficiency Anemia: a South Korean Nationwide Population-Based Cohort Study[J].Sci Adv, 2023, 9(43): eadg6194. [15] LI Y.Drug Induced Hematological Diseases(Part 1)[J].Chinese Journal For Clinicians(中国临床医生),2009, 37(4): 54-58. |